NTRA News and Press, Natera Inc. From 07/29/20

FinancialBuzz.com News Commentary New York, NY (7/29/2020) – The diagnostics industry is a large and diverse entity, with new innovative technology constantly under development. Diagnostic tests are usually conducted in laboratories, private or public, which are equipped with appropriat...

SAN CARLOS, Calif. , July 29, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2020 , after the market close on August 5, 2020 . Natera will...

SAN CARLOS, Calif. , July 14, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, has received the Force for Change Illuminator award from LWE, accepted by Sheetal Parmar , Natera's VP of Medical Affairs. The Force ...

Genetic testing is a way to identify how chromosomes, genes and proteins change, according to the US National Library of Medicine . So what are the top genetic testing stocks? There are currently thousands of genetic tests, with more being developed. As noted by the US National Library of...

Source : Natera Inc. Introduction: what is Natera? Formed in 2003, Natera Inc. ( NTRA ) has since become a major player in the diagnostics market operating with proprietary molecular and bioinformatics technology aiming to change the way global diseases are managed. They generate reven...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to invest in multiple biotech companies via one vehicle. The life science sector certainly holds a risk factor, and ETFs are a good way to enter th...

Natera's ( NTRA   -3.1% )  new lab  in Austin will provide 70,000 square foot space and add cutting-edge, automated lab equipment and capabilities. More news on: Natera, Inc., Healthcare stocks news Read more ...

SAN CARLOS, Calif. , June 22, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, is pleased to announce the expansion of its laboratory facility in Austin, Texas , supporting greater test processing capacity. This ...

Molecular testing services provider Natera ( NTRA +1.3% ) announces the commencement of enrollment in two clinical trials, CIRCULATE-Japan and BESPOKE CRC, evaluating clinical outcomes of its Signatera  molecular residual disease (MRD) test in patients with resectable (Stages II - IV...

SAN CARLOS, Calif. , June 18, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that enrollment has begun in the CIRCULATE-Japan and BESPOKE CRC trials, with both studies experiencing strong interest from centers ac...